CHNC to Seek Up to $3 Million Funding for Expansion of Existing Product Lines and Development of New Cannabis-Derived Therapeutics

Rhea-AI Summary

China Infrastructure Construction Corp. (OTC: CHNC) is seeking strategic partners to invest up to $3 million in its growth plans. The company aims to broaden its existing digital products and services, enhance staff from 60 to 250 by Q3 2022, and conduct research on cannabis benefits. CHNC also plans to establish a manufacturing facility for medical and nutraceutical products derived from cannabis. However, there is no guarantee that investments will be secured on favorable terms.

Positive

• Seeking up to $3 million investment to support growth.
• Plans to expand employee base from 60 to 250 by Q3 2022.
• Initiating clinical trials on cannabis benefits.
• Establishing a manufacturing facility for cannabis-derived products.

Negative

• No assurance that investments can be obtained on acceptable terms.

HOUSTON, TX, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- China Infrastructure Construction Corp. (OTC: CHNC) (dba Cannabis Bioscience International Holdings), announced today that it is actively seeking strategic partners to invest up to $3 million in two or three tranches although there can be no assurance that any such investment can be obtained on acceptable terms, or at all. The company has been diligently working around the clock actively entertaining proposals from quality groups that will bring proprietary knowledge and expertise to support and accelerate its ongoing revenue streams and build new revenue-generating centers in the U.S. and internationally.

“Our first priority is to continue to solidify the foundation of our existing digital products and services such as our Cannabis World Journals, eBooks, educational videos, sleep center and clinical studies,” said Henry Levinski, CHNC´s Treasurer.  “We have set challenging goals in all of these areas and are determined to reach or exceed them; for example, we will continue to gain our proper share of the market by featuring our products in new languages such as Mandarin, French, German and Hindi.”

The company will continue to invest in its internal staff of associates, which has grown from approximately 20 to over 60 within the past year. “We are very proud of the team we have built, and we intend to continue to add value through our association of professionals all striving for our common goal of stability and growth,” said Anne Graham, CHNC’s Corporate Attorney and VP of Operations. “With this additional funding we have set a goal of building our staff to 250 by the third quarter of 2022.”

Furthermore, we will also use part of this funding to start research on the medical benefits of cannabis and the implication of cannabinoids on body homeostasis with a 18-months clinical trial on healthy individuals and patients with pathologies associated with endocannabinoid system disorders; this research aims to provide the scientific data required to establish cannabis as a safe and effective alternative in various diseases.

More importantly, we will move to establish a manufacturing facility for a number of medical, nutraceutical, and vitamin supplement products utilizing therapeutic derivatives of cannabis to assist patients suffering from diseases such as cancer, multiple sclerosis, epilepsy and many more. We are committed to working within U.S. and international laws and will only develop and distribute our products and services accordingly.

Certainly, one of the characteristics of CHNC is innovation and we are convinced that investment focused on these areas will allow us to grow and continue to yield the investment-returns (ROI) experienced so far by our investors and much more. To learn more visit: https://www.chnc-hdh.com/

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

For more information contact us at:
info@pharmacologyuniversity.com
817/528-2475 for English
214/733-0868 for Spanish

FAQ

What is China Infrastructure Construction Corp. (CHNC) seeking from investors?

CHNC is seeking to attract up to $3 million in investment to support its growth initiatives.

What are the growth goals for CHNC's staff by 2022?

CHNC aims to increase its staff from 60 to 250 employees by the third quarter of 2022.

What type of research is CHNC planning to conduct?

CHNC plans to conduct 18-month clinical trials on the medical benefits of cannabis.

Why is CHNC planning to establish a manufacturing facility?

CHNC intends to create a manufacturing facility for medical and nutraceutical products derived from cannabis.

Is there any guarantee for the investment that CHNC is seeking?

CHNC has indicated there is no assurance that the investment can be obtained on acceptable terms.